<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">Trials</journal-id><journal-id journal-id-type="iso-abbrev">Trials</journal-id><journal-title-group><journal-title>Trials</journal-title></journal-title-group><issn pub-type="epub">1745-6215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25925591</article-id><article-id pub-id-type="pmc">4424595</article-id><article-id pub-id-type="publisher-id">724</article-id><article-id pub-id-type="doi">10.1186/s13063-015-0724-z</article-id><article-categories><subj-group subj-group-type="heading"><subject>Study Protocol</subject></subj-group></article-categories><title-group><article-title>Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Kubica</surname><given-names>Jacek</given-names></name><address><email>jkubica@cm.umk.pl</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><name><surname>Adamski</surname><given-names>Piotr</given-names></name><address><email>piotr.adamski@wp.eu</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Ostrowska</surname><given-names>Małgorzata</given-names></name><address><email>ostrowska.go@gmail.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Koziński</surname><given-names>Marek</given-names></name><address><email>marekkozinski@wp.pl</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Obońska</surname><given-names>Karolina</given-names></name><address><email>kalaobonska@op.pl</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><contrib contrib-type="author"><name><surname>Laskowska</surname><given-names>Ewa</given-names></name><address><email>laskowskaewa1@gmail.com</email></address><xref ref-type="aff" rid="Aff2"></xref></contrib><contrib contrib-type="author"><name><surname>Obońska</surname><given-names>Ewa</given-names></name><address><email>ewaobonska@onet.eu</email></address><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Grześk</surname><given-names>Grzegorz</given-names></name><address><email>ggrzesk@cm.umk.pl</email></address><xref ref-type="aff" rid="Aff3"></xref></contrib><contrib contrib-type="author"><name><surname>Winiarski</surname><given-names>Piotr</given-names></name><address><email>otolaryngologia@biziel.pl</email></address><xref ref-type="aff" rid="Aff4"></xref></contrib><contrib contrib-type="author"><name><surname>Paciorek</surname><given-names>Przemysław</given-names></name><address><email>p.paciorek@wp.pl</email></address><xref ref-type="aff" rid="Aff1"></xref></contrib><aff id="Aff1"><label></label>Department of Cardiology and Internal Medicine, Nicolaus Copernicus University, Collegium Medicum, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland </aff><aff id="Aff2"><label></label>Department of Principles of Clinical Medicine, Nicolaus Copernicus University, Collegium Medicum, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland </aff><aff id="Aff3"><label></label>Department of Pharmacology and Therapy, Nicolaus Copernicus University, Collegium Medicum, 9 Skłodowskiej-Curie Street, 85-094 Bydgoszcz, Poland </aff><aff id="Aff4"><label></label>Dr. J. Biziel Memorial University Hospital No. 2, 75 Ujejskiego Street, 85-168 Bydgoszcz, Poland </aff></contrib-group><pub-date pub-type="epub"><day>29</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="pmc-release"><day>29</day><month>4</month><year>2015</year></pub-date><pub-date pub-type="collection"><year>2015</year></pub-date><volume>16</volume><elocation-id>198</elocation-id><history><date date-type="received"><day>27</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>© Kubica et al.; licensee BioMed Central. 2015</copyright-statement><license license-type="open-access"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title><offsets xml_i="5289" xml_f="5299" txt_i="11" txt_f="21">Background</offsets></title><p><offsets xml_i="5310" xml_f="5724" txt_i="22" txt_f="436">Ticagrelor is an oral platelet P2Y12 receptor antagonist which is recommended for patients suffering from myocardial infarction, both with and without persistent ST segment elevation. Morphine is the first choice drug in pain alleviation in the same clinical subset. Recently a possible negative influence of morphine on the pharmacokinetics and antiplatelet effects of P2Y12 receptor blockers has been postulated.</offsets></p></sec><sec><title><offsets xml_i="5746" xml_f="5760" txt_i="438" txt_f="452">Methods/design</offsets></title><p><offsets xml_i="5771" xml_f="6775" txt_i="453" txt_f="1457">The IMPRESSION study is a phase IV, single center, randomized, double-blind, placebo-controlled clinical trial that is designed to assess the influence of morphine on the pharmacokinetics and pharmacodynamics of ticagrelor in patients with myocardial infarction. The study is planned to include up to 100 patients with myocardial infarction who will be randomized into one of two arms in a 1:1 ratio. Subjects in the intervention arm prior to the loading dose of ticagrelor (180 mg) will receive morphine (5 mg) intravenously, whereas patients in the control arm will receive a placebo prior to the loading dose of ticagrelor (180 mg). The pharmacokinetics of ticagrelor and its active metabolite (AR-C124910XX) will be assessed by liquid chromatography mass spectrometry. Platelet function testing in each patient will be performed using up to four different methods (platelet vasodilator-stimulated phosphoprotein assay, multiple electrode aggregometry, VerifyNow, and light transmission aggregometry).</offsets></p></sec><sec><title><offsets xml_i="6797" xml_f="6807" txt_i="1459" txt_f="1469">Discussion</offsets></title><p><offsets xml_i="6818" xml_f="7128" txt_i="1470" txt_f="1780">This study is expected to provide essential evidence-based data on the impact of morphine on the absorption of ticagrelor in patients with myocardial infarction as well as to shed some light on the suspected connection between morphine use and antiplatelet activity of ticagrelor in the same group of patients.</offsets></p></sec><sec><title><offsets xml_i="7150" xml_f="7168" txt_i="1782" txt_f="1800">Trial registration</offsets></title><p><offsets xml_i="7179" xml_f="7210" txt_i="1801" txt_f="1832">ClinicalTrials.gov identifier: </offsets><ext-link ext-link-type="uri" xlink:href="http://www.clinicaltrials.gov/ct2/show/NCT02217878"><offsets xml_i="7304" xml_f="7315" txt_i="1832" txt_f="1843">NCT02217878</offsets></ext-link><offsets xml_i="7326" xml_f="7344" txt_i="1843" txt_f="1861"> (14 August 2014).</offsets></p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Ticagrelor</kwd><kwd>Morphine</kwd><kwd>Myocardial infarction</kwd><kwd>Pharmacokinetics</kwd><kwd>Pharmacodynamics</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>© The Author(s) 2015</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title><offsets xml_i="7785" xml_f="7795" txt_i="1870" txt_f="1880">Background</offsets></title><p><offsets xml_i="7806" xml_f="8647" txt_i="1881" txt_f="2722">Platelet activation and aggregation play a pivotal role in the pathophysiology of acute coronary syndromes (ACS), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI). Dual antiplatelet therapy, consisting of aspirin and one of the P2Y12 receptor antagonists, constitutes the mainstay of ACS treatment. Achievement of adequate and timely platelet inhibition is of vast importance in the acute phase of myocardial infarction. Results of the PLATO trial have shown that therapy with ticagrelor, a novel platelet P2Y12 receptor inhibitor, compared with clopidogrel reduces not only the rate of death from vascular causes, myocardial infarction, or stroke, but also all-cause mortality, without concomitant increase in the rate of overall major bleeding, in patients with ACS [</offsets><xref ref-type="bibr" rid="CR1"><offsets xml_i="8679" xml_f="8680" txt_i="2722" txt_f="2723">1</offsets></xref><offsets xml_i="8687" xml_f="8688" txt_i="2723" txt_f="2724">,</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="8720" xml_f="8721" txt_i="2724" txt_f="2725">2</offsets></xref><offsets xml_i="8728" xml_f="8907" txt_i="2725" txt_f="2904">]. The superiority of ticagrelor over clopidogrel evidenced in the PLATO trial has been principally attributed to ticagrelor’s fast, potent, and uniform pharmacodynamic features [</offsets><xref ref-type="bibr" rid="CR2"><offsets xml_i="8939" xml_f="8940" txt_i="2904" txt_f="2905">2</offsets></xref><offsets xml_i="8947" xml_f="8948" txt_i="2905" txt_f="2906">,</offsets><xref ref-type="bibr" rid="CR3"><offsets xml_i="8980" xml_f="8981" txt_i="2906" txt_f="2907">3</offsets></xref><offsets xml_i="8988" xml_f="8990" txt_i="2907" txt_f="2909">].</offsets></p><p><offsets xml_i="8997" xml_f="9345" txt_i="2910" txt_f="3258">Based on the mentioned results, therapy with ticagrelor received class I B recommendation according to the European Society of Cardiology (ESC) in interventionally treated STEMI patients and in all moderate-to-high risk patients with ACS without persistent ST-segment elevation, including NSTEMI patients, regardless of initial treatment strategy [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="9377" xml_f="9378" txt_i="3258" txt_f="3259">4</offsets></xref><offsets xml_i="9385" xml_f="9386" txt_i="3259" txt_f="3260">,</offsets><xref ref-type="bibr" rid="CR5"><offsets xml_i="9418" xml_f="9419" txt_i="3260" txt_f="3261">5</offsets></xref><offsets xml_i="9426" xml_f="9623" txt_i="3261" txt_f="3458">]. Likewise, the American College of Cardiology Foundation and American Heart Association (ACCF/AHA) Task Force on Practice Guidelines recommend the use of ticagrelor in these subsets of patients [</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="9655" xml_f="9656" txt_i="3458" txt_f="3459">6</offsets></xref><offsets xml_i="9663" xml_f="9664" txt_i="3459" txt_f="3460">,</offsets><xref ref-type="bibr" rid="CR7"><offsets xml_i="9696" xml_f="9697" txt_i="3460" txt_f="3461">7</offsets></xref><offsets xml_i="9704" xml_f="9706" txt_i="3461" txt_f="3463">].</offsets></p><p><offsets xml_i="9713" xml_f="9871" txt_i="3464" txt_f="3622">The same ESC and ACCF/AHA guidelines recommend the use of morphine as a treatment of choice for pain relief in the clinical setting of myocardial infarction [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="9903" xml_f="9904" txt_i="3622" txt_f="3623">4</offsets></xref><offsets xml_i="9911" xml_f="9912" txt_i="3623" txt_f="3624">-</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="9944" xml_f="9945" txt_i="3624" txt_f="3625">6</offsets></xref><offsets xml_i="9952" xml_f="10375" txt_i="3625" txt_f="4048">]. However, these recommendations, although strong, are only based on expert consensus. Pain relief in patients presenting with acute myocardial infarction (AMI) is suggested to lead to decreased sympathetic activation, thus preventing vasoconstriction and subsequent increase in the workload of the heart. Additionally, apart from its analgesic effects, morphine also alleviates the work of breathing and reduces anxiety [</offsets><xref ref-type="bibr" rid="CR4"><offsets xml_i="10407" xml_f="10408" txt_i="4048" txt_f="4049">4</offsets></xref><offsets xml_i="10415" xml_f="10416" txt_i="4049" txt_f="4050">,</offsets><xref ref-type="bibr" rid="CR6"><offsets xml_i="10448" xml_f="10449" txt_i="4050" txt_f="4051">6</offsets></xref><offsets xml_i="10456" xml_f="10996" txt_i="4051" txt_f="4591">]. On the other hand, despite its favorable analgesic and sedative actions, morphine also exerts adverse effects, which include hypotension, bradycardia, respiratory depression, vomiting, and reduction of gastrointestinal motility. Importantly, both the safety and efficacy of morphine have never been tested in randomized trials in the ACS setting, while a large, retrospective analysis of the CRUSADE registry suggests that morphine administration may be associated with increased mortality in patients with non-ST-segment elevation ACS [</offsets><xref ref-type="bibr" rid="CR8"><offsets xml_i="11028" xml_f="11029" txt_i="4591" txt_f="4592">8</offsets></xref><offsets xml_i="11036" xml_f="11345" txt_i="4592" txt_f="4901">]. Some of the previously listed side effects of morphine could affect the intestinal absorption and thus the pharmacokinetics (PK) and pharmacodynamics (PD) of orally administered drugs which are concomitantly used with morphine. Note that currently all commercially available P2Y12 blockers are oral agents.</offsets></p><p><offsets xml_i="11352" xml_f="11642" txt_i="4902" txt_f="5192">In concordance with those facts, it was observed that morphine lags clopidogrel absorption, decreases plasma levels of clopidogrel and its active metabolite, and delays and diminishes antiplatelet effects of this thienopyridine, although this was observed in a group of healthy volunteers [</offsets><xref ref-type="bibr" rid="CR9"><offsets xml_i="11674" xml_f="11675" txt_i="5192" txt_f="5193">9</offsets></xref><offsets xml_i="11682" xml_f="11702" txt_i="5193" txt_f="5213">]. Moreover, Parodi </offsets><italic><offsets xml_i="11710" xml_f="11715" txt_i="5213" txt_f="5218">et al</offsets></italic><offsets xml_i="11724" xml_f="11923" txt_i="5218" txt_f="5417">. in their study comparing the PD of ticagrelor and prasugrel in STEMI patients reported that morphine administration may be associated with impaired antiplatelet effects of both investigated drugs [</offsets><xref ref-type="bibr" rid="CR10"><offsets xml_i="11956" xml_f="11958" txt_i="5417" txt_f="5419">10</offsets></xref><offsets xml_i="11965" xml_f="11967" txt_i="5419" txt_f="5421">].</offsets></p><p><offsets xml_i="11974" xml_f="12476" txt_i="5422" txt_f="5924">However, a definitive evidence of a possible interaction between morphine and the novel P2Y12 receptor antagonists may be obtained only in randomized studies. At present, no PK and PD data regarding the concurrent use of morphine and P2Y12 blockers in the ACS setting are available. Therefore, evidence-based verification of morphine’s influence on the PK and PD of ticagrelor and its active metabolite (AR-C124910XX) could provide a valuable insight into the knowledge regarding modern ACS management.</offsets></p></sec><sec id="Sec2" sec-type="materials|methods"><title><offsets xml_i="12537" xml_f="12551" txt_i="5926" txt_f="5940">Methods/design</offsets></title><sec id="Sec3"><title><offsets xml_i="12581" xml_f="12597" txt_i="5941" txt_f="5957">Study objectives</offsets></title><p><offsets xml_i="12608" xml_f="12977" txt_i="5958" txt_f="6327">The primary objective of the Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION) study is to test the hypothesis that intravenous administration of morphine prior to ticagrelor administration in patients with AMI alters the plasma concentrations of ticagrelor and its active metabolite.</offsets></p><p><offsets xml_i="12984" xml_f="13186" txt_i="6328" txt_f="6530">The secondary objective of this study is to determine whether intravenous administration of morphine prior to ticagrelor administration in AMI patients attenuates the antiplatelet effects of ticagrelor.</offsets></p><p><offsets xml_i="13193" xml_f="13406" txt_i="6531" txt_f="6744">Additionally, a predefined subanalysis has been planned to investigate which of the platelet reactivity assessment methods utilized in the study best reflects concentration of ticagrelor and its active metabolite.</offsets></p></sec><sec id="Sec4"><title><offsets xml_i="13438" xml_f="13465" txt_i="6746" txt_f="6773">Study design and population</offsets></title><p><offsets xml_i="13476" xml_f="14050" txt_i="6774" txt_f="7348">The IMPRESSION study is a phase IV, single center, randomized, double-blind, placebo-controlled, PK and PD clinical trial. The study population includes subjects presenting with AMI, including both STEMI and NSTEMI patients. After admission to the study center (Cardiology Clinic, Dr. A. Jurasz University Hospital, Bydgoszcz, Poland) and confirmation of the initial STEMI or NSTEMI diagnosis, patients will receive orally a 300-mg loading dose of plain aspirin and will be screened for eligibility for the study. The inclusion and exclusion criteria are as listed in Table </offsets><xref rid="Tab1" ref-type="table"><offsets xml_i="14084" xml_f="14085" txt_i="7348" txt_f="7349">1</offsets></xref><offsets xml_i="14092" xml_f="14439" txt_i="7349" txt_f="7696">. Eligible patients will be randomly assigned in a 1:1 ratio to one of two study arms. The patients in the intervention arm will receive 5 mg of morphine intravenously (IV) followed by a 180-mg loading dose of ticagrelor, whereas patients in the control arm will obtain 5 mg of a placebo IV followed by a 180-mg loading dose of ticagrelor (Figure </offsets><xref rid="Fig1" ref-type="fig"><offsets xml_i="14471" xml_f="14472" txt_i="7696" txt_f="7697">1</offsets></xref><offsets xml_i="14479" xml_f="14808" txt_i="7697" txt_f="8026">). Subsequently all patients will undergo a coronary angiography followed by percutaneous coronary intervention (PCI), if necessary. Blood samples for PK and PD assessment will be drawn at eight predefined time points during the first 12 hours after randomization, according to the blood sampling schedule as presented in Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="14840" xml_f="14841" txt_i="8026" txt_f="8027">2</offsets></xref><offsets xml_i="14848" xml_f="14982" txt_i="8027" txt_f="8161">. A telephone follow-up will be conducted at 30 days post-randomization, which will conclude the subject’s participation in the study.</offsets><table-wrap id="Tab1"><label><offsets xml_i="15011" xml_f="15018" txt_i="8161" txt_f="8168">Table 1</offsets></label><caption><p><offsets xml_i="15038" xml_f="15039" txt_i="8168" txt_f="8169">
</offsets><bold><offsets xml_i="15045" xml_f="15098" txt_i="8169" txt_f="8222">Inclusion and exclusion criteria for IMPRESSION study</offsets></bold><offsets xml_i="15105" xml_f="15106" txt_i="8222" txt_f="8223">
</offsets></p></caption><table frame="hsides" rules="groups"><tbody><tr valign="top"><td colspan="2"><offsets xml_i="15197" xml_f="15215" txt_i="8224" txt_f="8242">Inclusion Criteria</offsets></td></tr><tr valign="top"><td><offsets xml_i="15246" xml_f="15314" txt_i="8243" txt_f="8311">Provision of informed consent prior to any study-specific procedures</offsets></td><td><offsets xml_i="15323" xml_f="15376" txt_i="8312" txt_f="8365">Provision of informed consent for angiography and PCI</offsets></td></tr><tr valign="top"><td><offsets xml_i="15407" xml_f="15447" txt_i="8366" txt_f="8406">Diagnosis of acute STEMI or acute NSTEMI</offsets></td><td><offsets xml_i="15456" xml_f="15508" txt_i="8407" txt_f="8459">Male or non-pregnant female, aged 18 to 80 years old</offsets></td></tr><tr valign="top"><td colspan="2"><offsets xml_i="15551" xml_f="15569" txt_i="8460" txt_f="8478">Exclusion Criteria</offsets></td></tr><tr valign="top"><td><offsets xml_i="15600" xml_f="15685" txt_i="8479" txt_f="8564">Chest pain described by the patient as unbearable or patient’s request for analgesics</offsets></td><td><offsets xml_i="15694" xml_f="15753" txt_i="8565" txt_f="8624">History of major surgery or severe trauma (within 3 months)</offsets></td></tr><tr valign="top"><td><offsets xml_i="15784" xml_f="15848" txt_i="8625" txt_f="8689">Prior morphine administration during the current STEMI or NSTEMI</offsets></td><td><offsets xml_i="15857" xml_f="15932" txt_i="8690" txt_f="8765">Patients considered by the investigator to be at risk of bradycardic events</offsets></td></tr><tr valign="top"><td><offsets xml_i="15963" xml_f="16071" txt_i="8766" txt_f="8874">Treatment with ticlopidine, clopidogrel, prasugrel, or ticagrelor within 14 days before the study enrollment</offsets></td><td><offsets xml_i="16080" xml_f="16159" txt_i="8875" txt_f="8954">Second- or third-degree atrioventricular block during screening for eligibility</offsets></td></tr><tr valign="top"><td><offsets xml_i="16190" xml_f="16220" txt_i="8955" txt_f="8985">Hypersensitivity to ticagrelor</offsets></td><td><offsets xml_i="16229" xml_f="16254" txt_i="8986" txt_f="9011">Patient required dialysis</offsets></td></tr><tr valign="top"><td><offsets xml_i="16285" xml_f="16355" txt_i="9012" txt_f="9082">Current treatment with oral anticoagulant or chronic therapy with LMWH</offsets></td><td><offsets xml_i="16364" xml_f="16429" txt_i="9083" txt_f="9148">History of asthma or severe chronic obstructive pulmonary disease</offsets></td></tr><tr valign="top"><td><offsets xml_i="16460" xml_f="16475" txt_i="9149" txt_f="9164">Active bleeding</offsets></td><td><offsets xml_i="16484" xml_f="16524" txt_i="9165" txt_f="9205">Manifest infection or inflammatory state</offsets></td></tr><tr valign="top"><td><offsets xml_i="16555" xml_f="16589" txt_i="9206" txt_f="9240">History of intracranial hemorrhage</offsets></td><td><offsets xml_i="16598" xml_f="16653" txt_i="9241" txt_f="9296">Killip class III or IV during screening for eligibility</offsets></td></tr><tr valign="top"><td><offsets xml_i="16684" xml_f="16733" txt_i="9297" txt_f="9346">Recent gastrointestinal bleeding (within 30 days)</offsets></td><td><offsets xml_i="16742" xml_f="16761" txt_i="9347" txt_f="9366">Respiratory failure</offsets></td></tr><tr valign="top"><td><offsets xml_i="16792" xml_f="16824" txt_i="9367" txt_f="9399">History of coagulation disorders</offsets></td><td><offsets xml_i="16833" xml_f="16895" txt_i="9400" txt_f="9462">History of severe chronic heart failure (NYHA class III or IV)</offsets></td></tr><tr valign="top"><td><offsets xml_i="16926" xml_f="17083" txt_i="9463" txt_f="9620">Concomitant therapy with strong CYP3A inducers (rifampicin, phenytoin, carbamazepine, dexamethasone, phenobarbital) within 14 days and during study treatment</offsets></td><td><offsets xml_i="17092" xml_f="17284" txt_i="9621" txt_f="9813">Concomitant therapy with strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir)</offsets></td></tr><tr valign="top"><td><offsets xml_i="17315" xml_f="17359" txt_i="9814" txt_f="9858">Hemoglobin concentration less than 10.0 g/dl</offsets></td><td><offsets xml_i="17368" xml_f="17410" txt_i="9859" txt_f="9898">Platelet count less than &lt;100 x10^3/mcl</offsets></td></tr><tr valign="top"><td><offsets xml_i="17441" xml_f="17489" txt_i="9899" txt_f="9947">History of moderate or severe hepatic impairment</offsets></td><td><offsets xml_i="17498" xml_f="17521" txt_i="9948" txt_f="9971">Body weight below 50 kg</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="17567" xml_f="17784" txt_i="9972" txt_f="10189">LMWH: low-molecular-weight heparin; NSTEMI: non-ST-segment elevation myocardial infarction; NYHA: New York Heart Association; PCI: percutaneous coronary intervention; STEMI: ST-segment elevation myocardial infarction.</offsets></p></table-wrap-foot></table-wrap><fig id="Fig1"><label><offsets xml_i="17841" xml_f="17849" txt_i="10190" txt_f="10198">Figure 1</offsets></label><caption><p><offsets xml_i="17869" xml_f="17973" txt_i="10198" txt_f="10302">Trial schema for the IMPRESSION study. Legend: IV: intravenous; PCI: percutaneous coronary intervention.</offsets></p></caption><graphic xlink:href="13063_2015_724_Fig1_HTML" id="MO1"></graphic></fig><fig id="Fig2"><label><offsets xml_i="18081" xml_f="18089" txt_i="10303" txt_f="10311">Figure 2</offsets></label><caption><p><offsets xml_i="18109" xml_f="18158" txt_i="10311" txt_f="10360">Blood sampling schedule for the IMPRESSION study.</offsets></p></caption><graphic xlink:href="13063_2015_724_Fig2_HTML" id="MO2"></graphic></fig></p><p><offsets xml_i="18251" xml_f="18693" txt_i="10362" txt_f="10804">The study will be conducted in accordance with the principles contained in the Declaration of Helsinki, and the study site received approval from the Local Ethics Committee to conduct the study (Komisja Bioetyczna Uniwersytetu Mikołaja Kopernika w Toruniu przy Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy; study approval reference number KB 111/2014). Each patient will provide a written informed consent to participate in the study.</offsets></p></sec><sec id="Sec5"><title><offsets xml_i="18725" xml_f="18741" txt_i="10806" txt_f="10822">Pharmacokinetics</offsets></title><p><offsets xml_i="18752" xml_f="18935" txt_i="10823" txt_f="11006">Blood plasma concentrations of ticagrelor and AR-C124910XX will be evaluated using liquid chromatography mass spectrometry in samples obtained in eight predefined time points (Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="18967" xml_f="18968" txt_i="11006" txt_f="11007">2</offsets></xref><offsets xml_i="18975" xml_f="18977" txt_i="11007" txt_f="11009">).</offsets></p></sec><sec id="Sec6"><title><offsets xml_i="19009" xml_f="19025" txt_i="11011" txt_f="11027">Pharmacodynamics</offsets></title><p><offsets xml_i="19036" xml_f="19145" txt_i="11028" txt_f="11137">Assessment of ticagrelor’s antiplatelet effects will be performed using up to four different methods (Figure </offsets><xref rid="Fig3" ref-type="fig"><offsets xml_i="19177" xml_f="19178" txt_i="11137" txt_f="11138">3</offsets></xref><offsets xml_i="19185" xml_f="19330" txt_i="11138" txt_f="11283">). A platelet vasodilator-stimulated phosphoprotein (VASP) assay will be applied to all study participants at all predefined time points (Figure </offsets><xref rid="Fig2" ref-type="fig"><offsets xml_i="19362" xml_f="19363" txt_i="11283" txt_f="11284">2</offsets></xref><offsets xml_i="19370" xml_f="19952" txt_i="11284" txt_f="11866">). Multiple electrode aggregometry (MEA) will be used at all predefined time points for all study participants with the exception of those treated with glycoprotein IIb/IIIa (GP IIb/IIIa) receptor inhibitors. VerifyNow and light transmission aggregometry (LTA) will be applied for at least 30% of all enrolled study participants at all predefined time points. Measurements with VerifyNow and LTA will not be performed in patients treated with GP IIb/IIIa receptor inhibitors. Details regarding methods to be used for the assessment of platelet reactivity were previously described [</offsets><xref ref-type="bibr" rid="CR11"><offsets xml_i="19985" xml_f="19987" txt_i="11866" txt_f="11868">11</offsets></xref><offsets xml_i="19994" xml_f="19995" txt_i="11868" txt_f="11869">-</offsets><xref ref-type="bibr" rid="CR14"><offsets xml_i="20028" xml_f="20030" txt_i="11869" txt_f="11871">14</offsets></xref><offsets xml_i="20037" xml_f="20039" txt_i="11871" txt_f="11873">].</offsets><fig id="Fig3"><label><offsets xml_i="20061" xml_f="20069" txt_i="11873" txt_f="11881">Figure 3</offsets></label><caption><p><offsets xml_i="20089" xml_f="20266" txt_i="11881" txt_f="12058">Pharmacodynamic assessment schedule for IMPRESSION study. Legend: GP IIb/IIIa: glycoprotein IIb/IIIa; LTA: light transmission aggregometry; MEA: multiple electrode aggregometry.</offsets></p></caption><graphic xlink:href="13063_2015_724_Fig3_HTML" id="MO3"></graphic></fig></p></sec><sec id="Sec7"><title><offsets xml_i="20384" xml_f="20430" txt_i="12061" txt_f="12107">Treatment protocol and concomitant medications</offsets></title><p><offsets xml_i="20441" xml_f="21385" txt_i="12108" txt_f="13052">During their participation in the study, all patients will be treated according to the current ESC guidelines. Administration of GP IIb/IIIa receptor inhibitors will be restricted to bailout situations. Interventional cardiologists will be encouraged to use manual thrombectomy in case of visible thrombus. The choice of the access of the coronary invasive procedure (radial or femoral) and the type of implanted stent (drug-eluting stent [DES] or bare metal stent [BMS]) will be at the discretion of the operator, although high rates of radial access and DES implantation are expected to occur. From the loading dose of ticagrelor until completion of the study, all patients will receive maintenance doses of ticagrelor (90 mg) twice daily. In addition, standard therapy will include aspirin (75 to 100 mg daily), beta blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers, if not contraindicated.</offsets></p></sec><sec id="Sec8"><title><offsets xml_i="21417" xml_f="21432" txt_i="13054" txt_f="13069">Study endpoints</offsets></title><p><offsets xml_i="21443" xml_f="21536" txt_i="13070" txt_f="13163">The primary endpoint of this trial is the area under the plasma concentration-time curve (AUC</offsets><sub><offsets xml_i="21541" xml_f="21547" txt_i="13163" txt_f="13169">(0–12)</offsets></sub><offsets xml_i="21553" xml_f="21662" txt_i="13169" txt_f="13278">) for ticagrelor for the first 12 hours after the loading dose of ticagrelor. Secondary endpoints include AUC</offsets><sub><offsets xml_i="21667" xml_f="21673" txt_i="13278" txt_f="13284">(0–12)</offsets></sub><offsets xml_i="21679" xml_f="22014" txt_i="13284" txt_f="13619"> for AR-C124910XX, maximum concentration (Cmax) of ticagrelor and AR-C124910XX, time to Cmax for ticagrelor and AR-C124910XX, platelet reactivity index (PRI) assessed by VASP assay, area under the aggregation curve assessed by MEA, P2Y12 reaction units (PRU) assessed by VerifyNow, and ADP-induced platelet aggregation assessed by LTA.</offsets></p></sec><sec id="Sec9"><title><offsets xml_i="22046" xml_f="22052" txt_i="13621" txt_f="13627">Safety</offsets></title><p><offsets xml_i="22063" xml_f="22638" txt_i="13628" txt_f="14203">The following safety endpoints will be recorded: definite stent thrombosis according to the Academic Research Consortium criteria, major and minor, recurrent myocardial infarction according to the Third Universal Definition of Myocardial Infarction, all-cause death, stroke, and transient ischemic attack (TIA) according to definitions used in the PLATO trial, minor and major bleedings according to the BARC, PLATO, and TIMI criteria, dyspnea adverse events according to criteria used in the PLATO trial, bradyarrhythmic events according to criteria used in the PLATO trial.</offsets></p></sec><sec id="Sec10"><title><offsets xml_i="22671" xml_f="22681" txt_i="14205" txt_f="14215">Statistics</offsets></title><p><offsets xml_i="22692" xml_f="22979" txt_i="14216" txt_f="14503">Since there is no reference study examining the PK of ticagrelor in patients presenting with STEMI or NSTEMI, we decided to perform an internal pilot study of approximately 30 patients (15 patients for each arm) to estimate the final sample size. The means and standard deviations of AUC</offsets><sub><offsets xml_i="22984" xml_f="22990" txt_i="14503" txt_f="14509">(0–12)</offsets></sub><offsets xml_i="22996" xml_f="23280" txt_i="14509" txt_f="14793"> for ticagrelor in the first 33 patients assessed for patients who received morphine and for patients who received the placebo were 6,917 ± 4,920 and 10,379 ± 5,996 ng · h/ml, respectively. Based on these results and assuming a two-sided alpha value of 0.05, we calculated, using the </offsets><italic><offsets xml_i="23288" xml_f="23289" txt_i="14793" txt_f="14794">t</offsets></italic><offsets xml_i="23298" xml_f="23435" txt_i="14794" txt_f="14931">-test for independent variables, that enrollment of 68 patients would provide an 80% power to demonstrate a significant difference in AUC</offsets><sub><offsets xml_i="23440" xml_f="23446" txt_i="14931" txt_f="14937">(0–12)</offsets></sub><offsets xml_i="23452" xml_f="23617" txt_i="14937" txt_f="15102"> for ticagrelor between patients who received morphine prior to a loading dose of ticagrelor and those who received the placebo prior to the ticagrelor loading dose.</offsets></p><p><offsets xml_i="23624" xml_f="23703" txt_i="15103" txt_f="15182">Continuous variables will be compared between both study arms by the Student’s </offsets><italic><offsets xml_i="23711" xml_f="23712" txt_i="15182" txt_f="15183">t</offsets></italic><offsets xml_i="23721" xml_f="23747" txt_i="15183" txt_f="15209">-test or the Mann–Whitney </offsets><italic><offsets xml_i="23755" xml_f="23756" txt_i="15209" txt_f="15210">U</offsets></italic><offsets xml_i="23765" xml_f="24047" txt_i="15210" txt_f="15492"> test, depending on the presence or absence of the normal distribution (as assessed by the Kolmogorov-Smirnov test). Proportions will be compared by the Fisher exact test or chi-square test when appropriate. Pharmacokinetic calculations will be performed using a dedicated software.</offsets></p></sec></sec><sec id="Sec11" sec-type="discussion"><title><offsets xml_i="24108" xml_f="24118" txt_i="15495" txt_f="15505">Discussion</offsets></title><p><offsets xml_i="24129" xml_f="24940" txt_i="15506" txt_f="16317">The IMPRESSION study is a phase IV, single center, randomized, double-blind, placebo-controlled clinical trial that assesses the influence of morphine on the PK and antiplatelet effects of ticagrelor in patients with myocardial infarction. This trial will provide important information regarding the impact of morphine, the analgesic which is most commonly used in patients with AMI, on the absorption of ticagrelor in subjects presenting with STEMI and NSTEMI. Furthermore, the study could specify the suspected connection between alterations in ticagrelor absorption and modification of its antiplatelet activity. A disclosure of such drug-drug interaction in AMI patients could supply a significant evidence-based data source regarding concurrent use of ticagrelor and morphine in STEMI and NSTEMI treatment.</offsets></p></sec><sec id="Sec12"><title><offsets xml_i="24973" xml_f="24985" txt_i="16319" txt_f="16331">Trial status</offsets></title><p><offsets xml_i="24996" xml_f="25434" txt_i="16332" txt_f="16770">The first patient was enrolled in August 2014. Initially the IMPRESSION study was planned to include STEMI patients only. However, on 9 September 2014, after the approval of the Local Ethics Committee, the trial population was expanded to include subjects with NSTEMI as well. By 8 January 2015, 33% of planned patients were successfully included in the study. The baseline characteristics of the enrolled patients are presented in Table </offsets><xref rid="Tab2" ref-type="table"><offsets xml_i="25468" xml_f="25469" txt_i="16770" txt_f="16771">2</offsets></xref><offsets xml_i="25476" xml_f="25477" txt_i="16771" txt_f="16772">.</offsets><table-wrap id="Tab2"><label><offsets xml_i="25506" xml_f="25513" txt_i="16772" txt_f="16779">Table 2</offsets></label><caption><p><offsets xml_i="25533" xml_f="25534" txt_i="16779" txt_f="16780">
</offsets><bold><offsets xml_i="25540" xml_f="25564" txt_i="16780" txt_f="16804">Baseline characteristics</offsets></bold><offsets xml_i="25571" xml_f="25572" txt_i="16804" txt_f="16805">
</offsets></p></caption><table frame="hsides" rules="groups"><thead><tr valign="top"><th></th><th><offsets xml_i="25660" xml_f="25661" txt_i="16806" txt_f="16807">
</offsets><bold><offsets xml_i="25667" xml_f="25681" txt_i="16807" txt_f="16821">STEMI (n = 22)</offsets></bold><offsets xml_i="25688" xml_f="25689" txt_i="16821" txt_f="16822">
</offsets></th><th><offsets xml_i="25698" xml_f="25699" txt_i="16822" txt_f="16823">
</offsets><bold><offsets xml_i="25705" xml_f="25720" txt_i="16823" txt_f="16838">NSTEMI (n = 11)</offsets></bold><offsets xml_i="25727" xml_f="25728" txt_i="16838" txt_f="16839">
</offsets></th><th><offsets xml_i="25737" xml_f="25738" txt_i="16839" txt_f="16840">
</offsets><bold><offsets xml_i="25744" xml_f="25758" txt_i="16840" txt_f="16854">Total (n = 33)</offsets></bold><offsets xml_i="25765" xml_f="25766" txt_i="16854" txt_f="16855">
</offsets></th></tr></thead><tbody><tr valign="top"><td><offsets xml_i="25812" xml_f="25832" txt_i="16855" txt_f="16875">Age in years, median</offsets></td><td><offsets xml_i="25841" xml_f="25845" txt_i="16876" txt_f="16880">62.6</offsets></td><td><offsets xml_i="25854" xml_f="25858" txt_i="16881" txt_f="16885">62.4</offsets></td><td><offsets xml_i="25867" xml_f="25871" txt_i="16886" txt_f="16890">62.5</offsets></td></tr><tr valign="top"><td><offsets xml_i="25902" xml_f="25910" txt_i="16891" txt_f="16899">Age ≥ 70</offsets></td><td><offsets xml_i="25919" xml_f="25928" txt_i="16900" txt_f="16909">9 (40.9%)</offsets></td><td><offsets xml_i="25937" xml_f="25946" txt_i="16910" txt_f="16919">2 (18.2%)</offsets></td><td><offsets xml_i="25955" xml_f="25964" txt_i="16920" txt_f="16929">9 (27.3%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="25995" xml_f="26001" txt_i="16930" txt_f="16936">Female</offsets></td><td><offsets xml_i="26010" xml_f="26019" txt_i="16937" txt_f="16946">5 (22.7%)</offsets></td><td><offsets xml_i="26028" xml_f="26037" txt_i="16947" txt_f="16956">2 (18.2%)</offsets></td><td><offsets xml_i="26046" xml_f="26055" txt_i="16957" txt_f="16966">7 (21.2%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26086" xml_f="26098" txt_i="16967" txt_f="16979">Hypertension</offsets></td><td><offsets xml_i="26107" xml_f="26116" txt_i="16980" txt_f="16989">7 (31.8%)</offsets></td><td><offsets xml_i="26125" xml_f="26134" txt_i="16990" txt_f="16999">8 (72.7%)</offsets></td><td><offsets xml_i="26143" xml_f="26153" txt_i="17000" txt_f="17010">15 (45.5%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26184" xml_f="26201" txt_i="17011" txt_f="17028">Diabetes mellitus</offsets></td><td><offsets xml_i="26210" xml_f="26219" txt_i="17029" txt_f="17038">5 (22.7%)</offsets></td><td><offsets xml_i="26228" xml_f="26237" txt_i="17039" txt_f="17048">2 (18.2%)</offsets></td><td><offsets xml_i="26246" xml_f="26255" txt_i="17049" txt_f="17058">7 (21.2%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26286" xml_f="26298" txt_i="17059" txt_f="17071">Dyslipidemia</offsets></td><td><offsets xml_i="26307" xml_f="26317" txt_i="17072" txt_f="17082">19 (86.4%)</offsets></td><td><offsets xml_i="26326" xml_f="26335" txt_i="17083" txt_f="17092">8 (72.7%)</offsets></td><td><offsets xml_i="26344" xml_f="26354" txt_i="17093" txt_f="17103">27 (81.8%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26385" xml_f="26399" txt_i="17104" txt_f="17118">Current smoker</offsets></td><td><offsets xml_i="26408" xml_f="26417" txt_i="17119" txt_f="17128">9 (40.9%)</offsets></td><td><offsets xml_i="26426" xml_f="26435" txt_i="17129" txt_f="17138">6 (54.5%)</offsets></td><td><offsets xml_i="26444" xml_f="26454" txt_i="17139" txt_f="17149">15 (45.5%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26485" xml_f="26493" txt_i="17150" txt_f="17158">Prior MI</offsets></td><td><offsets xml_i="26502" xml_f="26510" txt_i="17159" txt_f="17167">1 (4.5%)</offsets></td><td><offsets xml_i="26519" xml_f="26528" txt_i="17168" txt_f="17177">3 (27.3%)</offsets></td><td><offsets xml_i="26537" xml_f="26546" txt_i="17178" txt_f="17187">4 (12.2%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26577" xml_f="26586" txt_i="17188" txt_f="17197">Prior PCI</offsets></td><td><offsets xml_i="26595" xml_f="26603" txt_i="17198" txt_f="17206">1 (4.5%)</offsets></td><td><offsets xml_i="26612" xml_f="26621" txt_i="17207" txt_f="17216">5 (45.5%)</offsets></td><td><offsets xml_i="26630" xml_f="26639" txt_i="17217" txt_f="17226">6 (18.2%)</offsets></td></tr><tr valign="top"><td><offsets xml_i="26670" xml_f="26680" txt_i="17227" txt_f="17237">Prior CABG</offsets></td><td><offsets xml_i="26689" xml_f="26690" txt_i="17238" txt_f="17239">0</offsets></td><td><offsets xml_i="26699" xml_f="26700" txt_i="17240" txt_f="17241">0</offsets></td><td><offsets xml_i="26709" xml_f="26710" txt_i="17242" txt_f="17243">0</offsets></td></tr><tr valign="top"><td><offsets xml_i="26741" xml_f="26752" txt_i="17244" txt_f="17255">BMI in kg/m</offsets><sup><offsets xml_i="26757" xml_f="26758" txt_i="17255" txt_f="17256">2</offsets></sup><offsets xml_i="26764" xml_f="26765" txt_i="17256" txt_f="17257">
</offsets></td><td><offsets xml_i="26774" xml_f="26778" txt_i="17258" txt_f="17262">28.4</offsets></td><td><offsets xml_i="26787" xml_f="26791" txt_i="17263" txt_f="17267">27.4</offsets></td><td><offsets xml_i="26800" xml_f="26804" txt_i="17268" txt_f="17272">28.1</offsets></td></tr></tbody></table><table-wrap-foot><p><offsets xml_i="26850" xml_f="26936" txt_i="17273" txt_f="17359">BMI: body mass index; CABG: coronary artery bypass surgery; MI: myocardial infarction.</offsets></p></table-wrap-foot></table-wrap></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>ACCF/AHA</term><def><p>American College of Cardiology Foundation and American Heart Association</p></def></def-item><def-item><term>ACS</term><def><p>acute coronary syndromes</p></def></def-item><def-item><term>AMI</term><def><p>acute myocardial infarction</p></def></def-item><def-item><term>AUC</term><def><p>area under the curve</p></def></def-item><def-item><term>BMS</term><def><p>bare metal stent</p></def></def-item><def-item><term>Cmax</term><def><p>maximum concentration</p></def></def-item><def-item><term>DES</term><def><p>drug-eluting stent</p></def></def-item><def-item><term>ESC</term><def><p>European Society of Cardiology</p></def></def-item><def-item><term>GP IIb/IIIa</term><def><p>glycoprotein IIb/IIIa</p></def></def-item><def-item><term>IV</term><def><p>intravenously</p></def></def-item><def-item><term>LTA</term><def><p>light transmission aggregometry</p></def></def-item><def-item><term>MEA</term><def><p>multiple electrode aggregometry</p></def></def-item><def-item><term>NSTEMI</term><def><p>non-ST-segment elevation myocardial infarction</p></def></def-item><def-item><term>PCI</term><def><p>percutaneous coronary intervention</p></def></def-item><def-item><term>PD</term><def><p>pharmacodynamics</p></def></def-item><def-item><term>PK</term><def><p>pharmacokinetics</p></def></def-item><def-item><term>PRI</term><def><p>platelet reactivity index</p></def></def-item><def-item><term>PRU</term><def><p>P2Y12 reaction units</p></def></def-item><def-item><term>STEMI</term><def><p>ST-segment elevation myocardial infarction.</p></def></def-item></def-list></glossary><fn-group><fn><p>Jacek Kubica and Piotr Adamski contributed equally to this work.</p></fn><fn><p><bold>Competing interests</bold></p><p>Dr. Marek Koziński and Dr. Grzegorz Grześk received honoraria for lectures from AstraZeneca. The authors declare that they no competing interests.</p></fn><fn><p><bold>Authors’ contributions</bold></p><p>JK conceived the study, participated in its design and its further development, and drafted the manuscript. PA participated in the design of this study and its further development and drafted the manuscript. MO, MK, KO, EL, and EO participated in the design of this study and its further development. GG, PW, and PP participated in the development of the study protocol. All authors read and approved the final version of the manuscript.</p></fn></fn-group><ack><title>Acknowledgements</title><p>We would like to thank all participating cardiology specialists and residents working in the Cardiology Clinic at Dr. A. Jurasz University Hospital, Bydgoszcz, Poland, who contributed their input by performing the initial screening of admitted patients. We also would like to thank the nursing staff working in the Intensive Cardiology Care Unit and in the Catheterization Laboratory, Cardiology Clinic at Dr. A. Jurasz University Hospital, Bydgoszcz, Poland for their assistance in the blood sample drawing. Moreover, we gratefully acknowledge Joanna Sikora for her input in the organizational and technical preparation of the study.</p><sec id="FPar1"><title>Funding</title><p>The study is funded by Collegium Medicum of Nicolaus Copernicus University and did not receive any external funding.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wallentin</surname><given-names>L</given-names></name><name><surname>Becker</surname><given-names>RC</given-names></name><name><surname>Budaj</surname><given-names>A</given-names></name><name><surname>Cannon</surname><given-names>CP</given-names></name><name><surname>Emanuelsson</surname><given-names>H</given-names></name><name><surname>Held</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>Ticagrelor versus clopidogrel in patients with acute coronary syndromes</article-title><source>N Engl J Med</source><year>2009</year><volume>361</volume><fpage>1045</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa0904327</pub-id><pub-id pub-id-type="pmid">19717846</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarese</surname><given-names>EP</given-names></name><name><surname>Buffon</surname><given-names>A</given-names></name><name><surname>Kozinski</surname><given-names>M</given-names></name><name><surname>Rychter</surname><given-names>M</given-names></name><name><surname>Obonska</surname><given-names>K</given-names></name><name><surname>Kunadian</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>A critical overview on ticagrelor in acute coronary syndromes</article-title><source>QJM</source><year>2013</year><volume>106</volume><fpage>105</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcs187</pub-id><pub-id pub-id-type="pmid">23097390</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Navarese</surname><given-names>EP</given-names></name><name><surname>Verdoia</surname><given-names>M</given-names></name><name><surname>Schaffer</surname><given-names>A</given-names></name><name><surname>Suriano</surname><given-names>P</given-names></name><name><surname>Kozinski</surname><given-names>M</given-names></name><name><surname>Castriota</surname><given-names>F</given-names></name><etal></etal></person-group><article-title>Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials</article-title><source>QJM</source><year>2011</year><volume>104</volume><fpage>561</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1093/qjmed/hcr069</pub-id><pub-id pub-id-type="pmid">21572108</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)</collab><name><surname>Steg</surname><given-names>PG</given-names></name><name><surname>James</surname><given-names>SK</given-names></name><name><surname>Atar</surname><given-names>D</given-names></name><name><surname>Badano</surname><given-names>LP</given-names></name><name><surname>Blömstrom-Lundqvist</surname><given-names>C</given-names></name><etal></etal></person-group><article-title>ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation</article-title><source>Eur Heart J</source><year>2012</year><volume>33</volume><fpage>2569</fpage><lpage>619</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehs215</pub-id><pub-id pub-id-type="pmid">22922416</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamm</surname><given-names>CW</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name><name><surname>Agewall</surname><given-names>S</given-names></name><name><surname>Bax</surname><given-names>J</given-names></name><name><surname>Boersma</surname><given-names>E</given-names></name><name><surname>Bueno</surname><given-names>H</given-names></name><etal></etal></person-group><article-title>ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)</article-title><source>Eur Heart J</source><year>2011</year><volume>32</volume><fpage>2999</fpage><lpage>3054</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehr236</pub-id><pub-id pub-id-type="pmid">21873419</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O’Gara</surname><given-names>PT</given-names></name><name><surname>Kushner</surname><given-names>FG</given-names></name><name><surname>Ascheim</surname><given-names>DD</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><name><surname>Chung</surname><given-names>MK</given-names></name><name><surname>De Lemos</surname><given-names>J</given-names></name><etal></etal></person-group><article-title>2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source>Catheter Cardiovasc Interv</source><year>2013</year><volume>82</volume><fpage>E1</fpage><lpage>27</lpage><pub-id pub-id-type="doi">10.1002/ccd.24776</pub-id><pub-id pub-id-type="pmid">23299937</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jneid</surname><given-names>H</given-names></name><name><surname>Anderson</surname><given-names>JL</given-names></name><name><surname>Wright</surname><given-names>RS</given-names></name><name><surname>Adams</surname><given-names>CD</given-names></name><name><surname>Bridges</surname><given-names>CR</given-names></name><name><surname>Casey</surname><given-names>DE</given-names><suffix>Jr</suffix></name><etal></etal></person-group><article-title>2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/Non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines</article-title><source>J Am Coll Cardiol</source><year>2012</year><volume>60</volume><fpage>645</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2012.06.004</pub-id><pub-id pub-id-type="pmid">22809746</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meine</surname><given-names>TJ</given-names></name><name><surname>Roe</surname><given-names>MT</given-names></name><name><surname>Chen</surname><given-names>AY</given-names></name><name><surname>Patel</surname><given-names>MR</given-names></name><name><surname>Washam</surname><given-names>JB</given-names></name><name><surname>Ohman</surname><given-names>EM</given-names></name><etal></etal></person-group><article-title>Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative</article-title><source>Am Heart J</source><year>2005</year><volume>149</volume><fpage>1043</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/j.ahj.2005.02.010</pub-id><pub-id pub-id-type="pmid">15976786</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hobl</surname><given-names>EL</given-names></name><name><surname>Stimpfl</surname><given-names>T</given-names></name><name><surname>Ebner</surname><given-names>J</given-names></name><name><surname>Schoergenhofer</surname><given-names>C</given-names></name><name><surname>Derhaschnig</surname><given-names>U</given-names></name><name><surname>Sunder-Plassmann</surname><given-names>R</given-names></name><etal></etal></person-group><article-title>Morphine decreases clopidogrel concentrations and effects: a randomized, double blind, placebo-controlled trial</article-title><source>J Am Coll Cardiol</source><year>2014</year><volume>63</volume><fpage>630</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.10.068</pub-id><pub-id pub-id-type="pmid">24315907</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parodi</surname><given-names>G</given-names></name><name><surname>Valenti</surname><given-names>R</given-names></name><name><surname>Bellandi</surname><given-names>B</given-names></name><name><surname>Migliorini</surname><given-names>A</given-names></name><name><surname>Marcucci</surname><given-names>R</given-names></name><name><surname>Comito</surname><given-names>V</given-names></name><etal></etal></person-group><article-title>Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>61</volume><fpage>1601</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.01.024</pub-id><pub-id pub-id-type="pmid">23500251</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubica</surname><given-names>A</given-names></name><name><surname>Kasprzak</surname><given-names>M</given-names></name><name><surname>Siller-Matula</surname><given-names>J</given-names></name><name><surname>Koziński</surname><given-names>M</given-names></name><name><surname>Pio Navarese</surname><given-names>E</given-names></name><name><surname>Obońska</surname><given-names>K</given-names></name><etal></etal></person-group><article-title>Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction</article-title><source>Eur J Pharmacol</source><year>2014</year><volume>742</volume><fpage>47</fpage><lpage>54</lpage><pub-id pub-id-type="doi">10.1016/j.ejphar.2014.08.009</pub-id><pub-id pub-id-type="pmid">25199965</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koziński</surname><given-names>M</given-names></name><name><surname>Obońska</surname><given-names>K</given-names></name><name><surname>Stankowska</surname><given-names>K</given-names></name><name><surname>Navarese</surname><given-names>EP</given-names></name><name><surname>Fabiszak</surname><given-names>T</given-names></name><name><surname>Stolarek</surname><given-names>W</given-names></name><etal></etal></person-group><article-title>Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up</article-title><source>Cardiol J</source><year>2014</year><volume>21</volume><fpage>547</fpage><lpage>56</lpage><pub-id pub-id-type="doi">10.5603/CJ.a2014.0026</pub-id><pub-id pub-id-type="pmid">24671900</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kozinski</surname><given-names>M</given-names></name><name><surname>Bielis</surname><given-names>L</given-names></name><name><surname>Wisniewska-Szmyt</surname><given-names>J</given-names></name><name><surname>Boinska</surname><given-names>J</given-names></name><name><surname>Stolarek</surname><given-names>W</given-names></name><name><surname>Marciniak</surname><given-names>A</given-names></name><etal></etal></person-group><article-title>Diurnal variation in the platelet inhibition by clopidogrel</article-title><source>Platelets</source><year>2011</year><volume>22</volume><fpage>579</fpage><lpage>87</lpage><pub-id pub-id-type="doi">10.3109/09537104.2011.582900</pub-id><pub-id pub-id-type="pmid">21627410</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tantry</surname><given-names>US</given-names></name><name><surname>Bonello</surname><given-names>L</given-names></name><name><surname>Aradi</surname><given-names>D</given-names></name><name><surname>Price</surname><given-names>MJ</given-names></name><name><surname>Jeong</surname><given-names>YH</given-names></name><name><surname>Angiolillo</surname><given-names>DJ</given-names></name><etal></etal></person-group><article-title>Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding</article-title><source>J Am Coll Cardiol</source><year>2013</year><volume>62</volume><fpage>2261</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1016/j.jacc.2013.07.101</pub-id><pub-id pub-id-type="pmid">24076493</pub-id></element-citation></ref></ref-list></back></article>